1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
2.
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar
|
3.
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Tanaka S and Arii S: Molecular targeted
therapies in hepatocellular carcinoma. Semin Oncol. 39:486–492.
2012. View Article : Google Scholar
|
6.
|
Wadhwa R, Taira K and Kaul SC: An Hsp70
family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and
where? Cell Stress Chaperones. 7:309–316. 2002. View Article : Google Scholar : PubMed/NCBI
|
7.
|
Wadhwa R, Takano S, Kaur K, et al:
Upregulation of mortalin/ mthsp70/Grp75 contributes to human
carcinogenesis. Int J Cancer. 118:2973–2980. 2006. View Article : Google Scholar : PubMed/NCBI
|
8.
|
Mizukoshi E, Suzuki M, Misono T, et al:
Cell-cycle dependent tyrosine phosphorylation on mortalin regulates
its interaction with fibroblast growth factor-1. Biochem Biophys
Res Commun. 280:1203–1209. 2001. View Article : Google Scholar : PubMed/NCBI
|
9.
|
Wadhwa R, Takano S, Robert M, et al:
Inactivation of tumor suppressor p53 by mot-2, a hsp70 family
member. J Biol Chem. 273:29586–29591. 1998. View Article : Google Scholar : PubMed/NCBI
|
10.
|
Wadhwa R, Yaguchi T, Hasan MK, Taira K and
Kaul SC: Mortalin-MPD (mevalonate pyrophosphate decarboxylase)
interactions and their role in control of cellular proliferation.
Biochem Biophys Res Commun. 302:735–742. 2003. View Article : Google Scholar : PubMed/NCBI
|
11.
|
Yi X, Luk JM, Lee NP, et al: Association
of mortalin (HSPA9) with liver cancer metastasis and prediction for
early tumor recurrence. Mol Cell Proteomics. 7:315–325. 2008.
View Article : Google Scholar : PubMed/NCBI
|
12.
|
Li Y, Tang Y, Ye L, et al: Establishment
of a hepatocellular carcinoma cell line with unique metastatic
characteristics through in vivo selection and screening for
metastasis-related genes through cDNA microarray. J Cancer Res Clin
Oncol. 129:43–51. 2003.
|
13.
|
Li Y, Tang ZY, Ye SL, et al: Establishment
of cell clones with different metastatic potential from the
metastatic hepatocellular carcinoma cell line MHCC97. World J
Gastroenterol. 7:630–636. 2001.PubMed/NCBI
|
14.
|
Edmondson HA and Steiner PE: Primary
carcinoma of the liver: a study of 100 cases among 48,900
necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Chen MH, Yip GW, Tse GM, et al: Expression
of basal keratins and vimentin in breast cancers of young women
correlates with adverse pathologic parameters. Mod Pathol.
21:1183–1191. 2008. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Weidner N, Semple JP, Welch WR and Folkman
J: Tumor angiogenesis and metastasis - correlation in invasive
breast carcinoma. N Engl J Med. 324:1–8. 1991. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
18.
|
Hartl FU: Molecular chaperones in cellular
protein folding. Nature. 381:571–579. 1996. View Article : Google Scholar : PubMed/NCBI
|
19.
|
Calderwood SK, Khaleque MA, Sawyer DB and
Ciocca DR: Heat shock proteins in cancer: chaperones of
tumorigenesis. Trends Biochem Sci. 31:164–172. 2006. View Article : Google Scholar : PubMed/NCBI
|
20.
|
Ma Z, Izumi H, Kanai M, Kabuyama Y, Ahn NG
and Fukasawa K: Mortalin controls centrosome duplication via
modulating centrosomal localization of p53. Oncogene. 25:5377–5390.
2006. View Article : Google Scholar : PubMed/NCBI
|
21.
|
Lu WJ, Lee NP, Kaul SC, et al:
Mortalin-p53 interaction in cancer cells is stress dependent and
constitutes a selective target for cancer therapy. Cell Death
Differ. 18:1046–1056. 2011. View Article : Google Scholar : PubMed/NCBI
|
22.
|
Dundas SR, Lawrie LC, Rooney PH and Murray
GI: Mortalin is over-expressed by colorectal adenocarcinomas and
correlates with poor survival. J Pathol. 205:74–81. 2005.
View Article : Google Scholar : PubMed/NCBI
|
23.
|
Chen X, Xu B, Li H, et al: Expression of
mortalin detected in human liver cancer by tissue microarrays. Anat
Rec. 294:1344–1351. 2011. View
Article : Google Scholar : PubMed/NCBI
|
24.
|
Kimura H, Nakajima T, Kagawa K, et al:
Angiogenesis in hepatocellular carcinoma as evaluated by CD34
immunohistochemistry. Liver. 18:14–19. 1998. View Article : Google Scholar : PubMed/NCBI
|
25.
|
Gupta GP and Massague J: Cancer
metastasis: building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
26.
|
Zhou Y, Mao H, Li S, et al: HSP72 inhibits
Smad3 activation and nuclear translocation in renal
epithelial-to-mesenchymal transition. J Am Soc Nephrol. 21:598–609.
2010. View Article : Google Scholar : PubMed/NCBI
|
27.
|
Li Y, Kang X and Wang Q: HSP70 decreases
receptor-dependent phosphorylation of Smad2 and blocks
TGF-beta-induced epithelial-mesenchymal transition. J Genet
Genomics. 38:111–116. 2011. View Article : Google Scholar : PubMed/NCBI
|